TY - JOUR
T1 - Hepatic Cancers Overview
T2 - Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in?
AU - Gans, Jared H.
AU - Lipman, Jeffrey
AU - Golowa, Yosef
AU - Kinkhabwala, Milan
AU - Kaubisch, Andreas
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/5
Y1 - 2019/5
N2 - Hepatocellular cancer (HCC) is most common primary liver malignancy in adults. Treatment for HCC is a multispecialty undertaking, with surgical, locoregional, and systemic options available. Choice of treatment depends upon patient and disease factors. Surgical therapy, including resection and transplantation, is the primary curative treatment and is best suited to patients with early disease. More advanced disease may be amenable to locoregional therapies to “bridge” to transplantation, downstage disease, or as destination therapy for unresectable cases. These include percutaneous ablation, transarterial therapy, external radiation, and radioembolization with yttrium-90 conjugated beads. Patients with more advanced disease may benefit most from systemic chemotherapeutic or small molecule inhibitor options available, many of which have only been recently FDA approved. Immunotherapy is the newest component of HCC treatment. The Y-90 consultant should be familiar with all modalities of HCC treatment and the interplay between them.
AB - Hepatocellular cancer (HCC) is most common primary liver malignancy in adults. Treatment for HCC is a multispecialty undertaking, with surgical, locoregional, and systemic options available. Choice of treatment depends upon patient and disease factors. Surgical therapy, including resection and transplantation, is the primary curative treatment and is best suited to patients with early disease. More advanced disease may be amenable to locoregional therapies to “bridge” to transplantation, downstage disease, or as destination therapy for unresectable cases. These include percutaneous ablation, transarterial therapy, external radiation, and radioembolization with yttrium-90 conjugated beads. Patients with more advanced disease may benefit most from systemic chemotherapeutic or small molecule inhibitor options available, many of which have only been recently FDA approved. Immunotherapy is the newest component of HCC treatment. The Y-90 consultant should be familiar with all modalities of HCC treatment and the interplay between them.
UR - http://www.scopus.com/inward/record.url?scp=85061669119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061669119&partnerID=8YFLogxK
U2 - 10.1053/j.semnuclmed.2019.01.001
DO - 10.1053/j.semnuclmed.2019.01.001
M3 - Review article
C2 - 30954182
AN - SCOPUS:85061669119
SN - 0001-2998
VL - 49
SP - 170
EP - 181
JO - Seminars in nuclear medicine
JF - Seminars in nuclear medicine
IS - 3
ER -